Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.